Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Open-label, Multi-cohort Study to Assess Safety and Efficacy of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers

NCT04350463 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT04350463
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04350463 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Open-label, Multi-cohort Study to Assess Safety and Efficacy of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers
Lead sponsor
Celgene
Phase
Phase 2
Overall status
Completed
Start date
July 14, 2020
Completion date
December 19, 2023
Enrollment
92 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms